Search Within

Weinberg Fellows

  1. "Principal Biostatisticians "
Formats
  1. Journal Article (15)
  2. Meeting Abstract (11)
  3. Correspondence (1)
  4. Research Letter (1)
Groups
  1. Department of Medicine (28)
  2. Epidemiology and Biostatistics (28)
  3. Hematology-Oncology Fellows (28)
  4. Principal Biostatisticians (28)
  5. Hematologic Malignancies, Division of (22)
  6. Center for Hematologic Malignancies (21)

More Groups

People
  1. Esther Drill (25)
  2. Andrew Zelenetz (18)
  3. Anita Kumar (17)
  4. Ariela Noy (17)
  5. Paul Hamlin (17)
  6. Colette Owens (16)

More People

Years
  1. 2025 (6)
  2. 2024 (4)
  3. 2023 (3)
  4. 2022 (5)
  5. 2021 (4)
  6. 2020 (1)

More Years

Publications
  1. Blood (11)
  2. Haematologica (3)
  3. Journal of Clinical Oncology (3)
  4. American Journal of Surgical Pathology (1)
  5. Blood Advances (1)
  6. Blood Cancer Journal (1)

More Publications

Publishers
  1. American Society of Hematology (12)
  2. American Society of Clinical Oncology (3)
  3. Ferrata Storti Foundation (3)
  4. Biomed Central Ltd (2)
  5. American Association for Cancer Research (1)
  6. American Medical Association (1)

More Publishers

Results (28)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Treatment outcomes and CNS relapse risk in patients with primary cutaneous DLBCL, leg-type in the rituximab era
    Correspondence

    Cassanello, G.; Drill, E.; Qiu, A.; Ewalt, M. D.; Hamlin, P.; Horwitz, S. M.; Joffe, E.; Kumar, A.; Moskowitz, A. J.; Noy, A.; more...
    Blood Cancer Journal (2025)

    Fulltext@MSK | Save
  • Outcomes of T-cell/histiocyte-rich large B-cell lymphoma treated with higher-intensity therapy in the rituximab era: Insights from a retrospective analysis
    Journal Article

    Luttwak, E.; Robin, E. T.; Drill, E.; Boardman, A.; Caron, P.; Epstein-Peterson, Z.; Falchi, L.; Ghione, P.; Hamlin, P. A.; Horwitz, S. M.; more...
    Leukemia and Lymphoma (2025)

    Fulltext@MSK | Save
  • Predictors of outcomes with covalent BTK inhibitor treatment in relapsed/refractory TP53-mutant mantle cell lymphoma
    Research Letter

    Uppal, M.; Joseph, A.; Drill, E.; Hamlin, P.; Falchi, L.; Noy, A.; Owens, C.; Epstein-Peterson, Z. D.; Salles, G.; Zelenetz, A. D.; more...
    British Journal of Haematology (2025)

    Fulltext@MSK | Save
  • Natural language processing of radiology reports to assess survival in patients with advanced melanoma
    Journal Article

    Das, J. P.; Eichholz, J.; Sevilimedu, V.; Gangai, N.; Khalil, D. N.; Postow, M. A.; Do, R. K. G.
    Cancers (2025)

    Fulltext@MSK | Save
  • Phase II trial of nivolumab plus doxorubicin, vinblastine, dacarbazine as frontline therapy in older adults with Hodgkin lymphoma
    Journal Article

    Torka, P.; Feldman, T.; Savage, K. J.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Perez, L.; Capadona, C.; Subzwari, S.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Rituximab and lenalidomide for the treatment of relapsed or refractory indolent non-Hodgkin lymphoma: Real-life experience
    Journal Article

    Cassanello, G.; Drill, E.; Rivas-Delgado, A.; Okwali, M.; Isgor, I.; Caron, P. C.; Epstein-Peterson, Z.; Ghione, P.; Hamlin, P. A.; Lue, J. K.; more...
    Haematologica (2025)

    Fulltext@MSK | Save
  • A prospective geriatric assessment (GA) study predicting toxicities in older adults (OA) with non-Hodgkin Lymphoma (NHL): Timed up and go test (TUG) time emerges as a functional vital sign
    Meeting Abstract

    Torka, P.; Drill, E.; Ganesan, N.; Truong, R.; Qiu, A.; Amador, W. R.; Oliveros, M.; Boardman, A. P.; Caron, P.; David, K. A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Pembrolizumab maintenance instead of autologous hematopoietic cell transplantation for patients with relapsed or refractory Hodgkin lymphoma in complete response after pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin
    Meeting Abstract

    Moskowitz, A.; Shah, G. L.; Ganesan, N.; Chang, T.; Drill, E.; Davey, T.; Hancock, H.; Munayirji, B.; Douglas, M.; Santarosa, A. M.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Treatment patterns and outcomes following progression of disease post-CAR-T therapy in relapsed or refractory mantle cell lymphoma: A multicenter analysis
    Meeting Abstract

    Epstein-Peterson, Z. D.; Lionel, A. C.; Joseph, A.; Drill, E.; Atallah-Yunes, S. A.; Brooks, T. R.; Chong, E. A.; Chong, E. R.; Dela Cruz, J.; Frank, M. J.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation
    Journal Article

    Epstein-Peterson, Z. D.; Drill, E.; Aypar, U.; Batlevi, C. L.; Caron, P.; Dogan, A.; Drullinsky, P.; Gerecitano, J.; Hamlin, P. A.; Ho, C.; more...
    Haematologica (2024)

    Fulltext@MSK | Save